What It Is:

Backed by scalable infrastructure, our patient networks offer vetted, ready-to-engage patients for insight generation, co-creation, multi-audience education, and peer-led support that drives activation and adherence.

Why It Matters:

Engaging with patient communities turns lived experience into better decisions, stronger programs, and more meaningful outcomes. We are experts in building long-lasting networks of all sizes, with a compliance infrastructure that enables enterprise-wide engagement.

How It Works:

Reverba Global is home to over 70 active patient communities, with one program running continuously for 23 years.

Our innovative technology platforms let clients tap into the power of these networks. Communication works both ways. Your teams can share essential information with maximum efficiency, while patients can share their own insights and stories to help guide fresh ways forward.

Let’s discuss how to activate an enterprise-wide Engagement Network for your organization.


The Latest

  • Perspective From Patients as Partners: Sustaining Patient Engagement Through Organizational Changes
    Perspective From Patients as Partners: Sustaining Patient Engagement Through Organizational Changes

    At Patients as Partners 2026, CEO Cheryl Lubbert shared how sustaining patient engagement through organizational change requires intentional design, with systems built to hold as teams, priorities, and programs shift.

  • Pharma USA 2026: AI Scales Reach in Pharma. But What Actually Changes Patient and HCP Behavior?
    Pharma USA 2026: AI Scales Reach in Pharma. But What Actually Changes Patient and HCP Behavior?

    AI is becoming a baseline expectation in pharma. At Pharma USA 2026, discussions reflected less focus on whether AI should be used and more on how it is being applied…

  • Approval Is Not the Finish Line: Turning Late-Stage Clinical Evidence Into Real-World Impact
    Approval Is Not the Finish Line: Turning Late-Stage Clinical Evidence Into Real-World Impact

    Late-stage clinical programs establish the evidence required for regulatory evaluation, but they do not guarantee adoption, access, or commercial performance. Translating that evidence into real-world impact requires patient-centered execution and…